Many dental schools offer implant clinical training at the pre- and postdoctoral levels, but little has been published on the clinical outcomes of implants placed in those programs. A post-entry chart review was conducted of all Branemark and Taper-Lock implants placed in a university clinic by faculty-student teams. Case information was gathered on data reporting forms and entered into a computer spreadsheet program. Survival rates were calculated as percentages. Cumulative implant survival was 96% for all 303 implants placed. Eight of the 12 implants that failed were placed by 2 operators, only 1 of whom was in the early stages of implant training. Branemark implant survival was 94.9% (n = 198) at 36 months; failures occurred between stage 2 and 3 months (n = 8) in mandibles and after 12 months (n = 2) in maxillae. Taper-Lock implant survival was 98.1% (n = 105) at 24 months; no mandibular failures occurred, but maxillary failures occurred before stage 2 (n = 1) and after 12 months of loading (n = 1). Taper-Lock implants exhibited a slightly higher (3.2%) cumulative survival rate at 24 months compared to Branemark implants. Differences in the numbers of implants placed (105 vs 198) and follow-up times (24 months vs 36 months) may have skewed the comparative results of Taper-Lock and Branemark implants, respectively, in this study. Implant survival for both systems was similar at 24 months of follow-up, and clinician experience did not appear to be an influencing variable on implant survival.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1563/1548-1336(2004)030<0023:RCRODI>2.0.CO;2 | DOI Listing |
Sci Rep
January 2025
Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
Pocket hematoma is a common and serious complication following cardiac implantable electronic device (CIED) implantation, contributing to significant morbidity and mortality. This study aimed to evaluate the efficacy of a novel pocket compression device in reducing pocket hematoma occurrence. We enrolled 242 patients undergoing CIED implantation, randomly assigning them to receive either the novel compression vest with a pressure cuff or conventional sandbag compression.
View Article and Find Full Text PDFBrachytherapy
January 2025
Department of Radiology, The Second People's Hospital of China Three Gorges University, Yichang, Hubei, China. Electronic address:
Objective: The objective of this study was to evaluate the efficacy and safety of TACE combined with 125I seeds (TACE-125I) in the treatment of recurrent HCC at complex sites after hepatectomy.
Methods: This study retrospectively analyzed the clinical data of recurrent HCC patients located at complex sites (such as large blood vessels, diaphragm dome, etc.) after hepatectomy from January 2012 to December 2023, all of whom received TACE-125I or TACE therapy.
Ann Med
December 2025
Heart Centre, Turku University Hospital, Turku, Finland.
Background: Several randomized controlled trials (RCTs) have investigated the benefits of atrial fibrillation (AF) screening. However, since none have shown a significant reduction in stroke rates, the impact of screening on clinical outcomes remains uncertain.
Materials And Methods: We conducted a systematic review and meta-analysis of RCTs reporting clinical outcomes of systematic AF screening in participants without known AF.
Pathogens
January 2025
Research Laboratory for Biofilms and Implant Associated Infections (BIOFILM LAB), University Hospital for Orthopaedics and Traumatology, Medical University of Innsbruck, Müllerstraße 44, 6020 Innsbruck, Austria.
Background: The burden of prosthetic joint infection in combination with antibiotic-resistant bacterial strains is a rising dilemma for patients experiencing total joint replacements. Around 0.8-2% of patients experience prosthetic joint infections, while up to 21% of patients are considered fatal cases after 5 years.
View Article and Find Full Text PDFJ Clin Med
January 2025
Department of Cardiology, Angiology and Intensive Care, Philipps University Marburg, 35043 Marburg, Germany.
Emerging evidence suggests the role of mechanical circulatory support (MCS) devices in the therapy of refractory cardiogenic shock (CS). However, largerandomized trials addressing the role of Impella in the therapy of infarct-associated CS are sparse. As such, evidence coming from comprehensive retrospective studies or meta-analyses is of major importance in order to clarify the role of the Impella device in this setting.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!